W
Wolfgang Rutsch
Researcher at Humboldt University of Berlin
Publications - 120
Citations - 16271
Wolfgang Rutsch is an academic researcher from Humboldt University of Berlin. The author has contributed to research in topics: Myocardial infarction & Restenosis. The author has an hindex of 46, co-authored 120 publications receiving 16034 citations. Previous affiliations of Wolfgang Rutsch include Charing Cross Hospital & Erasmus University Rotterdam.
Papers
More filters
Journal ArticleDOI
A Comparison of Balloon-Expandable-Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery Disease
Patrick W. Serruys,P. de Jaegere,Ferdinand Kiemeneij,Carlos Macaya,Wolfgang Rutsch,Gr. Heyndrickx,H. Emanuelsson,Jean Marco,Victor Legrand,P. Materne +9 more
TL;DR: The clinical and angiographic outcomes were better in patients who received a stent than in those who received standard coronary angioplasty, however, this benefit was achieved at the cost of a significantly higher risk of vascular complications at the access site and a longer hospital stay.
Journal ArticleDOI
Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention: REPLACE-2 Randomized Trial
A. Michael Lincoff,John A. Bittl,Robert A. Harrington,Frederick Feit,Neal S. Kleiman,J. Daniel Jackman,Ian J. Sarembock,David J. Cohen,Douglas Spriggs,Ramin Ebrahimi,Gadi Keren,Jeffrey Carr,Eric A. Cohen,Amadeo Betriu,Walter Desmet,Dean J. Kereiakes,Wolfgang Rutsch,Robert G. Wilcox,Pim J. de Feyter,Alec Vahanian,Eric J. Topol +20 more
TL;DR: Bivalirudin with provisional Gp IIb/IIIa blockade is statistically not inferior to heparin plus planned Gp IIIa blockade during contemporary PCI with regard to suppression of acute ischemic end points and is associated with less bleeding.
Journal ArticleDOI
Benefit of Abciximab in Patients with Refractory Unstable Angina in Relation to Serum Troponin T Levels
Christian W. Hamm,Christopher Heeschen,Britta U. Goldmann,Alec Vahanian,Jennifer Adgey,Carlos Macaya Miguel,Wolfgang Rutsch,Juergen Berger,Jille Kootstra,Maarten L. Simoons +9 more
TL;DR: The serum troponin T level, which is considered to be a surrogate marker for thrombus formation, identifies a high-risk subgroup of patients with refractory unstable angina suitable for coronary angioplasty who will particularly benefit from antiplatelet treatment with abciximab.
Journal ArticleDOI
RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTION: Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator
M. Verstraete,M Bory,Desire Collen,Raimund Erbel,R.J. Lennane,Detlef G. Mathey,H.-R. Michels,M. Schartl,Rainer Uebis,R Bernard,Ronald W. Brower,D.P. de Bono,W. Huhmann,Jacobus Lubsen,J. Meyer,Wolfgang Rutsch,W. Schmidt,R. Von Essen +17 more
TL;DR: In this article, the frequency of coronary patency was found to be higher after intravenous administration of recombinant human tissue-type plasminogen activator (rt-PA) than after IV intravenous streptokinase.
Journal ArticleDOI
Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter.
Bruno Scheller,Christoph Hehrlein,Wolfgang Bocksch,Wolfgang Rutsch,Dariush Haghi,Ulrich Dietz,Michael Böhm,Ulrich Speck +7 more
TL;DR: A randomized, double-blind, multicenter trial to compare the effects of a balloon catheter coated with paclitaxel (3 μg per square millimeter of balloon surface area) with those of an uncoated balloons catheter in coronary angioplasty found no significant differences.